Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 679-688

  Draht, Muriel X G ^a   Smits, Kim M ^a   Tournier, Benjamin ^b   Jooste, Valerie ^c   Chapusot, Caroline ^b   Carvalho, Beatriz ^d   Cleven, Arjen H G ^a   Derks, Sarah ^d   Wouters, Kim A D ^a   Belt, Eric J T ^d   Stockmann, Hein B A C ^e   Bril, Herman ^e   Weijenberg, Matty P ^a   van den Brandt, Piet A ^a   de Bruïne, Adriaan P ^a   Herman, James G ^f   Meijer, Gerrit A ^d   Piard, Françoise ^b   Melotte, Veerle ^a   Van Engeland, Manon ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Infection and Immunology   (Netherlands)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Colon cancer; Colorectal cancer; DNA methylation; Methylation marker; Prognostic biomarker; REarranged during transfection (RET)

Indexed keywords

PROTEIN RET;

AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METHYLATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; COLON; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECTUM; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECTUM;

EID: 84899477967     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.01.011     Document Type: Article

References (48)

1. Arighi E., Borrello M., Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005, 16:441-467.
2. Barault L., Charon-Barra C., Jooste V., de la Vega M.F., Martin L., Roignot P., Rat P., Bouvier A.M., Laurent-Puig P., Faivre J., Chapusot C., Piard F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008, 68:8541-8546.
3. Belt E.J., te Velde E.A., Krijgsman O., Brosens R.P., Tijssen M., van Essen H.F., Stockmann H.B., Bril H., Carvalho B., Ylstra B., Bonjer H.J., Meijer G.A. High lymph node yield is related to microsatellite instability in colon cancer. Ann. Surg. Oncol. 2012, 19:1222-1230.
4. Belt E.J., van Stijn M.F., Bril H., de Lange-de Klerk E.S., Meijer G.A., Meijer S., Stockmann H.B. Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Ann. Surg. Oncol. 2010, 17:3203-3211.
5. Benson A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., McAllister P., Van Cutsem E., Brouwers M., Charette M., Haller D.G. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J.Clin. Oncol. 2004, 22:3408-3419.
6. Betge J., Langner C. Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. Acta Gastro-enterologica Belgica 2011, 74:516-529.
7. Brink M., de Goeij A.F., Weijenberg M.P., Roemen G.M., Lentjes M.H., Pachen M.M., Smits K.M., de Bruine A.P., Goldbohm R.A., van den Brandt P.A. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003, 24:703-710.
8. Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P. RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons. J.Biol. Chem. 2011, 286:14628-14638.
9. Cavel O., Shomron O., Shabtay A., Vital J., Trejo-Leider L., Weizman N., Krelin Y., Fong Y., Wong R.J., Amit M., Gil Z. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 2012, 72:5733-5743.
10. Chan T.A., Glockner S., Yi J.M., Chen W., Van Neste L., Cope L., Herman J.G., Velculescu V., Schuebel K.E., Ahuja N., Baylin S.B. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008, 5:e114.
11. Clark-Langone K.M., Sangli C., Krishnakumar J., Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 2010, 10:691.
12. Claus R., Wilop S., Hielscher T., Sonnet M., Dahl E., Galm O., Jost E., Plass C. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics 2012, 7:772-780.
13. Compton C.C., Greene F.L. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 2004, 54:295-308.
14. Derks S., Lentjes M.H., Hellebrekers D.M., de Bruine A.P., Herman J.G., van Engeland M. Methylation-specific PCR unraveled. Cell Oncol. 2004, 26:291-299.
15. Diaz-Rodriguez E., GarcÃa-Lavandeira M., Perez-Romero S., Senra A., Caãibano C., Palmero I., Borrello M., Dieguez C., Alvarez C. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Oncogene 2012, 31:2824-2835.
16. Draht M.X., Riedl R.R., Niessen H., Carvalho B., Meijer G.A., Herman J.G., van Engeland M., Melotte V., Smits K.M. Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics 2012, 4:179-194.
17. Fretwell V.L., Ang C.W., Tweedle E.M., Rooney P.S. The impact of lymph node yield on Duke's B and C colorectal cancer survival. Colorectal Dis. 2010, 12:995-1000.
18. Goldschneider D., Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010, 29:1865-1882.
19. Graziano F., Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann. Oncol. 2003, 14:1026-1038.
20. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U S A 1996, 93:9821-9826.
21. Hermanek P., Scheibe O., Spiessl B., Wagner G. TNM classification of malignant tumors: a new 1987 edition. Der Pathologe 1987, 8:137.
22. Klump B., Nehls O., Okech T., Hsieh C.J., Gaco V., Gittinger F.S., Sarbia M., Borchard F., Greschniok A., Gruenagel H.H., Porschen R., Gregor M. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 2004, 19:23-42.
23. Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004, 23:29-39.
24. Krtolica K., Krajnovic M., Usaj-Knezevic S., Babic D., Jovanovic D., Dimitrijevic B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J. Gastroenterol. WJG 2007, 13:1187-1194.
25. Lenehan P.F., Boardman L.A., Riegert-Johnson D., De Petris G., Fry D.W., Ohrnberger J., Heyman E.R., Gerard B., Almal A.A., Worzel W.P. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer 2012, 118:5234-5244.
26. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C., Asco ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J.Clin. Oncol. 2006, 24:5313-5327.
27. Lugli A., Karamitopoulou E., Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br. J. Cancer 2012, 106:1713-1717.
28. Luo Y., Tsuchiya K.D., Il Park D., Fausel R., Kanngurn S., Welcsh P., Dzieciatkowski S., Wang J., Grady W.M. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 2012.
29. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
30. Melotte V., Lentjes M.H., van den Bosch S.M., Hellebrekers D.M., de Hoon J.P., Wouters K.A., Daenen K.L., Partouns-Hendriks I.E., Stessels F., Louwagie J., Smits K.M., Weijenberg M.P., Sanduleanu S., Khalid-de Bakker C.A., Oort F.A., Meijer G.A., Jonkers D.M., Herman J.G., de Bruine A.P., van Engeland M. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J.Natl. Cancer Inst. 2009, 101:916-927.
31. Mokarram P., Kumar K., Brim H., Naghibalhossaini F., Saberi-firoozi M., Nouraie M., Green R., Lee E., Smoot D.T., Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. PLoS One 2009, 4:e7012.
32. Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin. Cancer Res. 2010, 16:5936-5941.
33. Plaza-Menacho I., Burzynski G.M., de Groot J.W., Eggen B.J., Hofstra R.M. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 2006, 22:627-636.
34. Runeberg-Roos P., Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann. Med. 2007, 39:572-580.
35. Salazar R., Roepman P., Capella G., Moreno V., Simon I., Dreezen C., Lopez-Doriga A., Santos C., Marijnen C., Westerga J., Bruin S., Kerr D., Kuppen P., van de Velde C., Morreau H., Van Velthuysen L., Glas A.M., Van't Veer L.J., Tollenaar R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.Clin. Oncol. 2011, 29:17-24.
36. Sasselli V., Pachnis V., Burns A. The enteric nervous system. Dev. Biol. 2012, 366:64-73.
37. Simons C.C., Hughes L.A., Smits K.M., Khalid-de Bakker C.A., de Bruine A.P., Carvalho B., Meijer G.A., Schouten L.J., van den Brandt P.A., Weijenberg M.P., van Engeland M. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann. Oncol. 2013, 24:2048-2056.
38. Sobin L.H., Fleming I.D. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804.
39. Tanaka M., Chang P., Li Y., Li D., Overman M., Maru D.M., Sethi S., Phillips J., Bland G.L., Abbruzzese J.L., Eng C. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin. Cancer Res. 2011, 17:4531-4540.
40. Tournier B., Chapusot C., Courcet E., Martin L., Lepage C., Faivre J., Piard F. Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer 2012, 12:12.
41. Tsai H.L., Chu K.S., Huang Y.H., Su Y.C., Wu J.Y., Kuo C.H., Chen C.W., Wang J.Y. Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J.Surg. Oncol. 2009, 100:736-743.
42. Umetani N., Takeuchi H., Fujimoto A., Shinozaki M., Bilchik A.J., Hoon D.S. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin. Cancer Res. 2004, 10:7475-7483.
43. van den Brandt P.A., Goldbohm R.A., van 't Veer P., Volovics A., Hermus R.J., Sturmans F. A large-scale prospective cohort study on diet and cancer in The Netherlands. J.Clin. Epidemiol. 1990, 43:285-295.
44. Van den Brandt P.A., Schouten L.J., Goldbohm R.A., Dorant E., Hunen P.M. Development of a record linkage protocol for use in the Dutch cancer registry for epidemiological research. Int. J. Epidemiol. 1990, 19:553-558.
45. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A.J., Thibodeau S.N., Jass J., Haile R., Laird P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
46. Yi J., Dhir M., Van Neste L., Downing S., Jeschke J., Glãckner S., de Freitas Calmon M., Hooker C., Funes J., Boshoff C., Smits K., van Engeland M., Weijenberg M., Iacobuzio-Donahue C., Herman J., Schuebel K., Baylin S., Ahuja N. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res. 2011, 17:1535-1545.
47. Yi J.M., Dhir M., Van Neste L., Downing S.R., Jeschke J., Glockner S.C., de Freitas Calmon M., Hooker C.M., Funes J.M., Boshoff C., Smits K.M., van Engeland M., Weijenberg M.P., Iacobuzio-Donahue C.A., Herman J.G., Schuebel K.E., Baylin S.B., Ahuja N. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res. 2011, 17:1535-1545.
48. Zeng Q., Cheng Y., Zhu Q., Yu Z., Wu X., Huang K., Zhou M., Han S., Zhang Q. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J.Int. Med. Res. 2008, 36:656-664.